Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir.

de Weger VA, Stuurman FE, Koolen SLW, Moes JJ, Hendrikx JJMA, Sawicki E, Thijssen B, Keessen M, Rosing H, Mergui-Roelvink M, Huitema ADR, Nuijen B, Beijnen JH, Schellens JHM, Marchetti S.

Clin Cancer Res. 2019 Sep 15;25(18):5466-5474. doi: 10.1158/1078-0432.CCR-17-2299. Epub 2019 Jun 19.

PMID:
31217201
2.

Use of leftovers of monoclonal antibody products after partial extraction - A microbiological safety study.

Arnamo AH, Huitema AD, Beijnen JH, Nuijen B.

J Oncol Pharm Pract. 2019 Jun 2:1078155219850297. doi: 10.1177/1078155219850297. [Epub ahead of print]

PMID:
31156055
3.

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.

Wang L, Leite de Oliveira R, Huijberts S, Bosdriesz E, Pencheva N, Brunen D, Bosma A, Song JY, Zevenhoven J, Los-de Vries GT, Horlings H, Nuijen B, Beijnen JH, Schellens JHM, Bernards R.

Cell. 2018 May 31;173(6):1413-1425.e14. doi: 10.1016/j.cell.2018.04.012. Epub 2018 May 10.

4.

Solubility and bioavailability improvement of pazopanib hydrochloride.

Herbrink M, Groenland SL, Huitema ADR, Schellens JHM, Beijnen JH, Steeghs N, Nuijen B.

Int J Pharm. 2018 Jun 10;544(1):181-190. doi: 10.1016/j.ijpharm.2018.04.037. Epub 2018 Apr 19.

PMID:
29680279
5.

Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients.

Herbrink M, Nuijten M, Nuijen B, Huitema ADR, Beijnen JH, Hendriks VM, Blanken P, Janmohamed A, van den Brink W.

J Clin Psychopharmacol. 2018 Jun;38(3):212-217. doi: 10.1097/JCP.0000000000000862.

PMID:
29620701
6.

Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and 11C-Erlotinib PET.

Verheijen RB, Yaqub M, Sawicki E, van Tellingen O, Lammertsma AA, Nuijen B, Schellens JHM, Beijnen JH, Huitema ADR, Hendrikse NH, Steeghs N.

J Nucl Med. 2018 Jun;59(6):973-979. doi: 10.2967/jnumed.117.195800. Epub 2017 Nov 24.

7.

Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.

Herbrink M, de Vries N, Rosing H, Huitema ADR, Nuijen B, Schellens JHM, Beijnen JH.

Biomed Chromatogr. 2018 Apr;32(4). doi: 10.1002/bmc.4147. Epub 2017 Dec 19.

PMID:
29165815
8.

Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of Dexamphetamine in human plasma.

Herbrink M, Thijssen B, Hillebrand MJX, Rosing H, Schellens JHM, Nuijen B, Beijnen JH.

J Pharm Biomed Anal. 2018 Jan 30;148:259-264. doi: 10.1016/j.jpba.2017.10.009. Epub 2017 Oct 18.

PMID:
29059615
9.

Thermal stability study of crystalline and novel spray-dried amorphous nilotinib hydrochloride.

Herbrink M, Vromans H, Schellens J, Beijnen J, Nuijen B.

J Pharm Biomed Anal. 2018 Jan 30;148:182-188. doi: 10.1016/j.jpba.2017.10.001. Epub 2017 Oct 12.

PMID:
29040935
10.

A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir.

de Weger VA, Stuurman FE, Hendrikx JJMA, Moes JJ, Sawicki E, Huitema ADR, Nuijen B, Thijssen B, Rosing H, Keessen M, Mergui-Roelvink M, Beijnen JH, Schellens JHM, Marchetti S.

Eur J Cancer. 2017 Nov;86:217-225. doi: 10.1016/j.ejca.2017.09.010. Epub 2017 Oct 12.

PMID:
29031170
11.

Improving the solubility of nilotinib through novel spray-dried solid dispersions.

Herbrink M, Schellens JHM, Beijnen JH, Nuijen B.

Int J Pharm. 2017 Aug 30;529(1-2):294-302. doi: 10.1016/j.ijpharm.2017.07.010. Epub 2017 Jul 8.

PMID:
28689964
12.

High-Tech Drugs in Creaky Formulations.

Herbrink M, Nuijen B, Schellens JHM, Beijnen JH.

Pharm Res. 2017 Sep;34(9):1751-1753. doi: 10.1007/s11095-017-2185-4. Epub 2017 May 30.

PMID:
28560695
13.

HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia.

Samuels S, Marijne Heeren A, Zijlmans HJMAA, Welters MJP, van den Berg JH, Philips D, Kvistborg P, Ehsan I, Scholl SME, Nuijen B, Schumacher TNM, van Beurden M, Jordanova ES, Haanen JBAG, van der Burg SH, Kenter GG.

Cancer Immunol Immunother. 2017 Sep;66(9):1163-1173. doi: 10.1007/s00262-017-2006-y. Epub 2017 Apr 27.

PMID:
28451790
14.

Fast and Adequate Liquid Chromatography-Tandem Mass Spectrometric Determination of Z-endoxifen Serum Levels for Therapeutic Drug Monitoring.

de Krou S, Rosing H, Nuijen B, Schellens JH, Beijnen JH.

Ther Drug Monit. 2017 Apr;39(2):132-137. doi: 10.1097/FTD.0000000000000372.

PMID:
28045782
15.

Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies.

Sawicki E, Schellens JH, Beijnen JH, Nuijen B.

Drug Dev Ind Pharm. 2017 Apr;43(4):584-594. doi: 10.1080/03639045.2016.1274901. Epub 2017 Jan 8.

PMID:
28010129
16.

Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar.

Sawicki E, Verheijen RB, Huitema AD, van Tellingen O, Schellens JH, Nuijen B, Beijnen JH, Steeghs N.

Drug Deliv Transl Res. 2017 Feb;7(1):125-131. doi: 10.1007/s13346-016-0346-3.

PMID:
27864786
17.

Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique.

Sawicki E, Schellens JH, Beijnen JH, Nuijen B.

Cancer Treat Rev. 2016 Nov;50:247-263. doi: 10.1016/j.ctrv.2016.09.012. Epub 2016 Sep 20. Review.

PMID:
27776286
18.

Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.

Herbrink M, de Vries N, Rosing H, Huitema AD, Nuijen B, Schellens JH, Beijnen JH.

Ther Drug Monit. 2016 Dec;38(6):649-656.

PMID:
27749781
19.

Inherent formulation issues of kinase inhibitors.

Herbrink M, Schellens JH, Beijnen JH, Nuijen B.

J Control Release. 2016 Oct 10;239:118-27. doi: 10.1016/j.jconrel.2016.08.036. Epub 2016 Aug 28. Review.

PMID:
27578098
20.

Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel.

Sawicki E, Beijnen JH, Schellens JH, Nuijen B.

Int J Pharm. 2016 Sep 25;511(2):765-73. doi: 10.1016/j.ijpharm.2016.07.068. Epub 2016 Jul 29.

PMID:
27480397
21.

Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar.

Sawicki E, Hillebrand MJ, Rosing H, Schellens JHM, Nuijen B, Beijnen JH.

J Pharm Anal. 2016 Aug;6(4):268-275. doi: 10.1016/j.jpha.2016.04.005. Epub 2016 Apr 23.

22.

A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine.

Jacobs BA, Meulenaar J, Rosing H, Pluim D, Tibben MM, de Vries N, Nuijen B, Huitema AD, Beijnen JH, Schellens JH, Marchetti S.

Cancer Chemother Pharmacol. 2016 Jun;77(6):1201-7. doi: 10.1007/s00280-016-3035-5. Epub 2016 Apr 21.

PMID:
27103124
23.

Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial.

Nuijten M, Blanken P, van de Wetering B, Nuijen B, van den Brink W, Hendriks VM.

Lancet. 2016 May 28;387(10034):2226-34. doi: 10.1016/S0140-6736(16)00205-1. Epub 2016 Mar 22.

PMID:
27015909
24.

Variability in bioavailability of small molecular tyrosine kinase inhibitors.

Herbrink M, Nuijen B, Schellens JH, Beijnen JH.

Cancer Treat Rev. 2015 May;41(5):412-22. doi: 10.1016/j.ctrv.2015.03.005. Epub 2015 Mar 20. Review.

PMID:
25818541
25.

Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy.

Mehta AM, Van den Hoven JM, Rosing H, Hillebrand MJ, Nuijen B, Huitema AD, Beijnen JH, Verwaal VJ.

Int J Pharm. 2015 Feb 1;479(1):23-7. doi: 10.1016/j.ijpharm.2014.12.025. Epub 2014 Dec 20.

PMID:
25535649
26.

Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype.

Gomez-Eerland R, Nuijen B, Heemskerk B, van Rooij N, van den Berg JH, Beijnen JH, Uckert W, Kvistborg P, Schumacher TN, Haanen JB, Jorritsma A.

Hum Gene Ther Methods. 2014 Oct;25(5):277-87. doi: 10.1089/hgtb.2014.004. Epub 2014 Sep 22.

27.

Development of an extended-release formulation of capecitabine making use of in vitro-in vivo correlation modelling.

Meulenaar J, Keizer RJ, Beijnen JH, Schellens JH, Huitema AD, Nuijen B.

J Pharm Sci. 2014 Feb;103(2):478-84. doi: 10.1002/jps.23779. Epub 2013 Dec 5.

PMID:
24311366
28.

Long term stability of lyophilized plasmid DNA pDERMATT.

van der Heijden I, Beijnen JH, Nuijen B.

Int J Pharm. 2013 Sep 10;453(2):648-50. doi: 10.1016/j.ijpharm.2013.06.010. Epub 2013 Jun 19.

PMID:
23792100
29.

Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet.

Moes JJ, Stuurman FE, Hendrikx JJ, Marchetti S, Huitema AD, Beijnen JH, Schellens JH, Nuijen B.

Drug Deliv Transl Res. 2013 Jun;3(3):243-51. doi: 10.1007/s13346-012-0127-6.

PMID:
25788133
30.

Transposon leads to contamination of clinical pDNA vaccine.

van der Heijden I, Gomez-Eerland R, van den Berg JH, Oosterhuis K, Schumacher TN, Haanen JB, Beijnen JH, Nuijen B.

Vaccine. 2013 Jul 11;31(32):3274-80. doi: 10.1016/j.vaccine.2013.05.022. Epub 2013 May 23.

PMID:
23707695
31.

Taxanes: old drugs, new oral formulations.

Jibodh RA, Lagas JS, Nuijen B, Beijnen JH, Schellens JH.

Eur J Pharmacol. 2013 Oct 5;717(1-3):40-6. doi: 10.1016/j.ejphar.2013.02.058. Epub 2013 May 7. Review.

PMID:
23660368
32.

Complement activation by PEGylated liposomes containing prednisolone.

van den Hoven JM, Nemes R, Metselaar JM, Nuijen B, Beijnen JH, Storm G, Szebeni J.

Eur J Pharm Sci. 2013 May 13;49(2):265-71. doi: 10.1016/j.ejps.2013.03.007. Epub 2013 Mar 22.

PMID:
23528740
33.

Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.

Stuurman FE, Nuijen B, Beijnen JH, Schellens JH.

Clin Pharmacokinet. 2013 Jun;52(6):399-414. doi: 10.1007/s40262-013-0040-2. Review.

PMID:
23420518
34.

Slow dissolution behaviour of amorphous capecitabine.

Meulenaar J, Beijnen JH, Schellens JH, Nuijen B.

Int J Pharm. 2013 Jan 30;441(1-2):213-7. doi: 10.1016/j.ijpharm.2012.11.041. Epub 2012 Dec 5.

PMID:
23219704
35.

Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel.

Moes J, Koolen S, Huitema A, Schellens J, Beijnen J, Nuijen B.

Eur J Pharm Biopharm. 2013 Jan;83(1):87-94. doi: 10.1016/j.ejpb.2012.09.016. Epub 2012 Oct 17.

PMID:
23085332
36.

Cyclodextrin as membrane protectant in spray-drying and freeze-drying of PEGylated liposomes.

van den Hoven JM, Metselaar JM, Storm G, Beijnen JH, Nuijen B.

Int J Pharm. 2012 Nov 15;438(1-2):209-16. doi: 10.1016/j.ijpharm.2012.08.046. Epub 2012 Aug 31.

PMID:
22960501
37.

Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial.

Boekhout AH, Vincent AD, Dalesio OB, van den Bosch J, Foekema-Töns JH, Adriaansz S, Sprangers S, Nuijen B, Beijnen JH, Schellens JH.

J Clin Oncol. 2011 Oct 10;29(29):3862-8. doi: 10.1200/JCO.2010.33.1298. Epub 2011 Sep 12.

PMID:
21911720
38.

Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001).

Moes JJ, Koolen SL, Huitema AD, Schellens JH, Beijnen JH, Nuijen B.

Int J Pharm. 2011 Nov 28;420(2):244-50. doi: 10.1016/j.ijpharm.2011.08.041. Epub 2011 Sep 2.

PMID:
21907780
39.

Liposomal drug formulations in the treatment of rheumatoid arthritis.

van den Hoven JM, Van Tomme SR, Metselaar JM, Nuijen B, Beijnen JH, Storm G.

Mol Pharm. 2011 Aug 1;8(4):1002-15. doi: 10.1021/mp2000742. Epub 2011 Jun 17. Review.

PMID:
21634436
40.

Optimizing the therapeutic index of liposomal glucocorticoids in experimental arthritis.

van den Hoven JM, Hofkens W, Wauben MH, Wagenaar-Hilbers JP, Beijnen JH, Nuijen B, Metselaar JM, Storm G.

Int J Pharm. 2011 Sep 20;416(2):471-7. doi: 10.1016/j.ijpharm.2011.03.025. Epub 2011 Apr 2.

PMID:
21440612
41.

DNA vaccination in oncology: current status, opportunities and perspectives.

van den Berg JH, Oosterhuis K, Beijnen JH, Nuijen B, Haanen JB.

Curr Clin Pharmacol. 2010 Aug;5(3):218-25. Review.

PMID:
20406167
42.

Naked plasmid DNA formulation: effect of different disaccharides on stability after lyophilisation.

Quaak SG, Haanen JB, Beijnen JH, Nuijen B.

AAPS PharmSciTech. 2010 Mar;11(1):344-50. doi: 10.1208/s12249-010-9391-2. Epub 2010 Mar 4.

43.

Synthetic vehicles for DNA vaccination.

van den Berg JH, Nuijen B, Schumacher TN, Haanen JB, Storm G, Beijnen JH, Hennink WE.

J Drug Target. 2010 Jan;18(1):1-14. doi: 10.3109/10611860903278023.

PMID:
19814658
44.

Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity.

van den Berg JH, Oosterhuis K, Hennink WE, Storm G, van der Aa LJ, Engbersen JF, Haanen JB, Beijnen JH, Schumacher TN, Nuijen B.

J Control Release. 2010 Jan 25;141(2):234-40. doi: 10.1016/j.jconrel.2009.09.005. Epub 2009 Sep 12.

PMID:
19751778
45.

DNA tattoo vaccination: effect on plasmid purity and transfection efficiency of different topoisoforms.

Quaak SG, van den Berg JH, Oosterhuis K, Beijnen JH, Haanen JB, Nuijen B.

J Control Release. 2009 Oct 15;139(2):153-9. doi: 10.1016/j.jconrel.2009.06.033. Epub 2009 Jul 4.

PMID:
19580829
46.

Lipopolysaccharide contamination in intradermal DNA vaccination: toxic impurity or adjuvant?

van den Berg JH, Quaak SG, Beijnen JH, Hennink WE, Storm G, Schumacher TN, Haanen JB, Nuijen B.

Int J Pharm. 2010 May 5;390(1):32-6. doi: 10.1016/j.ijpharm.2009.06.031. Epub 2009 Jul 2.

PMID:
19576975
47.

Development and validation of an anion-exchange LC-UV method for the quantification and purity determination of the DNA plasmid pDERMATT.

Quaak SG, Nuijen B, Haanen JB, Beijnen JH.

J Pharm Biomed Anal. 2009 Feb 20;49(2):282-8. doi: 10.1016/j.jpba.2008.11.011. Epub 2008 Nov 19.

PMID:
19111423
48.

Purity profile of the indoloquinone anticancer agent EO-9 and chemical stability of EO-9 freeze dried with 2-hydroxypropyl-beta-cyclodextrin.

van der Schoot SC, Vainchtein LD, Nuijen B, Gore A, Mirejovsky D, Lenaz L, Beijnen JH.

Pharmazie. 2008 Nov;63(11):796-805.

PMID:
19069239
49.

Complexation study of the anticancer agent EO-9 with 2-hydroxypropyl-beta-cyclodextrin.

Beijnen JH, van der Schoot SC, Nuijen B, Flesch FM, Gore A, Mirejovsky D, Lenaz L.

Drug Dev Ind Pharm. 2008 Oct;34(10):1130-9. doi: 10.1080/03639040801974261 .

PMID:
18663657
50.

GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial.

Quaak SG, van den Berg JH, Toebes M, Schumacher TN, Haanen JB, Beijnen JH, Nuijen B.

Eur J Pharm Biopharm. 2008 Oct;70(2):429-38. doi: 10.1016/j.ejpb.2008.05.002. Epub 2008 May 17.

PMID:
18606527

Supplemental Content

Loading ...
Support Center